vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Bandwidth Inc. (BAND). Click either name above to swap in a different company.
Bandwidth Inc. is the larger business by last-quarter revenue ($208.8M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). Bandwidth Inc. runs the higher net margin — 1.9% vs -14.6%, a 16.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 20.1%). Bandwidth Inc. produced more free cash flow last quarter ($-1.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 9.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
AXSM vs BAND — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $208.8M |
| Net Profit | $-28.6M | $4.0M |
| Gross Margin | — | 37.3% |
| Operating Margin | -13.8% | 60.5% |
| Net Margin | -14.6% | 1.9% |
| Revenue YoY | 65.0% | 20.1% |
| Net Profit YoY | 61.9% | 200.0% |
| EPS (diluted) | $-0.55 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $208.8M | ||
| Q4 25 | $196.0M | $207.7M | ||
| Q3 25 | $171.0M | $191.9M | ||
| Q2 25 | $150.0M | $180.0M | ||
| Q1 25 | $121.5M | $174.2M | ||
| Q4 24 | $118.8M | $210.0M | ||
| Q3 24 | $104.8M | $193.9M | ||
| Q2 24 | $87.2M | $173.6M |
| Q1 26 | — | $4.0M | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-1.2M | ||
| Q2 25 | $-48.0M | $-4.9M | ||
| Q1 25 | $-59.4M | $-3.7M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $413.0K | ||
| Q2 24 | $-79.3M | $4.1M |
| Q1 26 | — | 37.3% | ||
| Q4 25 | — | 37.6% | ||
| Q3 25 | — | 38.5% | ||
| Q2 25 | — | 39.8% | ||
| Q1 25 | — | 41.0% | ||
| Q4 24 | — | 36.4% | ||
| Q3 24 | — | 37.7% | ||
| Q2 24 | — | 37.3% |
| Q1 26 | — | 60.5% | ||
| Q4 25 | -13.8% | -1.9% | ||
| Q3 25 | -27.0% | -1.0% | ||
| Q2 25 | -24.5% | -2.1% | ||
| Q1 25 | -46.9% | -2.7% | ||
| Q4 24 | -61.1% | -1.3% | ||
| Q3 24 | -59.8% | -0.5% | ||
| Q2 24 | -89.5% | -3.5% |
| Q1 26 | — | 1.9% | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -0.6% | ||
| Q2 25 | -32.0% | -2.7% | ||
| Q1 25 | -48.9% | -2.1% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 0.2% | ||
| Q2 24 | -91.0% | 2.3% |
| Q1 26 | — | $-0.08 | ||
| Q4 25 | $-0.55 | $-0.10 | ||
| Q3 25 | $-0.94 | $-0.04 | ||
| Q2 25 | $-0.97 | $-0.16 | ||
| Q1 25 | $-1.22 | $-0.13 | ||
| Q4 24 | $-1.54 | $0.27 | ||
| Q3 24 | $-1.34 | $0.01 | ||
| Q2 24 | $-1.67 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $47.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $405.7M |
| Total Assets | $689.8M | $984.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $47.3M | ||
| Q4 25 | $322.9M | $111.3M | ||
| Q3 25 | $325.3M | $80.4M | ||
| Q2 25 | $303.0M | $68.1M | ||
| Q1 25 | $300.9M | $41.7M | ||
| Q4 24 | $315.4M | $83.8M | ||
| Q3 24 | $327.3M | $79.9M | ||
| Q2 24 | $315.7M | $76.4M |
| Q1 26 | — | $405.7M | ||
| Q4 25 | $88.3M | $400.0M | ||
| Q3 25 | $73.7M | $392.7M | ||
| Q2 25 | $73.1M | $384.5M | ||
| Q1 25 | $53.2M | $345.4M | ||
| Q4 24 | $57.0M | $312.5M | ||
| Q3 24 | $92.9M | $336.6M | ||
| Q2 24 | $102.9M | $307.4M |
| Q1 26 | — | $984.2M | ||
| Q4 25 | $689.8M | $1.1B | ||
| Q3 25 | $669.3M | $1.0B | ||
| Q2 25 | $639.8M | $1.0B | ||
| Q1 25 | $596.7M | $964.4M | ||
| Q4 24 | $568.5M | $989.2M | ||
| Q3 24 | $561.5M | $1.0B | ||
| Q2 24 | $548.2M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | $-1.0M |
| FCF MarginFCF / Revenue | -9.6% | -0.5% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $38.6M | ||
| Q3 25 | $1.0M | $22.2M | ||
| Q2 25 | $-32.4M | $31.7M | ||
| Q1 25 | $-43.4M | $-3.1M | ||
| Q4 24 | $-26.2M | $36.5M | ||
| Q3 24 | $-18.6M | $20.5M | ||
| Q2 24 | $-30.1M | $24.4M |
| Q1 26 | — | $-1.0M | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | -0.5% | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 49.55× | ||
| Q2 24 | — | 6.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
